ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
14.01
-0.10 (-0.71%)
At close: Nov 15, 2024, 4:00 PM
13.79
-0.22 (-1.57%)
After-hours: Nov 15, 2024, 5:08 PM EST
ARS Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 2.57 | 0.03 | 1.32 | 5.51 | 17.84 |
| Revenue Growth (YoY) | 8460.00% | -97.72% | -76.10% | -69.13% | - |
| Cost of Revenue | 19.87 | 20.07 | 17.12 | 20.27 | 14.07 |
| Gross Profit | -17.3 | -20.04 | -15.8 | -14.77 | 3.77 |
| Selling, General & Admin | 43.21 | 47.48 | 18.66 | 4.69 | 4.23 |
| Operating Expenses | 43.21 | 47.48 | 18.66 | 4.69 | 4.23 |
| Operating Income | -60.51 | -67.52 | -34.46 | -19.45 | -0.47 |
| Interest Expense | - | - | - | -0.8 | -0.4 |
| Currency Exchange Gain (Loss) | - | - | - | - | -0.2 |
| Other Non Operating Income (Expenses) | 3.94 | 5.98 | 1.12 | 0.01 | 0 |
| EBT Excluding Unusual Items | -56.57 | -61.54 | -33.34 | -20.24 | -1.07 |
| Gain (Loss) on Sale of Investments | 7.47 | 6.88 | -0.29 | - | - |
| Gain (Loss) on Sale of Assets | - | 0.3 | - | - | - |
| Pretax Income | -49.1 | -54.37 | -34.68 | -20.24 | -1.07 |
| Net Income | -49.1 | -54.37 | -34.68 | -20.24 | -1.07 |
| Net Income to Common | -49.1 | -54.37 | -34.68 | -20.24 | -1.07 |
| Shares Outstanding (Basic) | 97 | 95 | 40 | 29 | 20 |
| Shares Outstanding (Diluted) | 97 | 95 | 40 | 29 | 20 |
| Shares Change (YoY) | 9.54% | 138.30% | 38.39% | 42.81% | - |
| EPS (Basic) | -0.51 | -0.57 | -0.87 | -0.70 | -0.05 |
| EPS (Diluted) | -0.51 | -0.57 | -0.87 | -0.70 | -0.05 |
| Free Cash Flow | -46.03 | -59.44 | -40.28 | -17.62 | 9.07 |
| Free Cash Flow Per Share | -0.48 | -0.62 | -1.01 | -0.61 | 0.45 |
| Gross Margin | - | - | - | -268.20% | 21.11% |
| Operating Margin | -2356.15% | -225066.67% | -2618.54% | -353.32% | -2.63% |
| Profit Margin | -1912.15% | -181216.67% | -2635.41% | -367.65% | -5.97% |
| Free Cash Flow Margin | -1792.48% | -198136.67% | -3060.56% | -319.94% | 50.86% |
| EBITDA | -60.44 | -67.45 | -34.43 | -19.24 | -0.46 |
| EBITDA Margin | - | - | - | - | -2.60% |
| D&A For EBITDA | 0.06 | 0.07 | 0.03 | 0.21 | 0.01 |
| EBIT | -60.51 | -67.52 | -34.46 | -19.45 | -0.47 |
| EBIT Margin | - | - | - | - | -2.63% |
| Revenue as Reported | 2.54 | - | - | - | 17.84 |
Source: S&P Capital IQ. Standard template.
Financial Sources.